Table 3.
Baseline Characteristics of Patients by Study
| Study | Mean age | Gender (% male:female) | Ethnicity | FEV1 % predicted | Reversibility (%) |
|---|---|---|---|---|---|
| FP/FORM studies | |||||
| 1 | 43 | 35:65 | White 74.6% Black 2.1% Asian 0.4% Hispanic 19.6% Other 3.2% |
67 | NR |
| 2 | 42 | 46:54 | White 98.9% Black 0.4% Asian 0.6% |
73 | 28 |
| Lasserson et al (32) Cochrane review of single inhaler FP/SAL versus single inhaler BUD/FORM | |||||
| Aalbers, 2004 (35) BUD/FORM | 46 | 45:55 | NR | 84 | NR |
| FP/SAL | 46 | 49:51 | NR | 85 | NR |
| Busse, 2008 (36) BUD/FORM | 39 | 34:66 | White 82.0% Black 13.8% Other 4.2% |
79 | NR |
| FP/SAL | 39 | 43:57 | White 84.0% Black 12.3% Other 3.7% |
78 | NR |
| COMPASS (37) BUD/FORM | 38 | 41:59 | NR | 73 | 25 |
| (Kuna, 2007) FP/SAL | 38 | 43:57 | NR | 73 | 23 |
| EXCEL(38) BUD/FORM | 47 | 41:59 | NR | 79 | 24 |
| (Dahl, 2006) FP/SAL | 46 | 44:56 | NR | 79 | 20 |
| Ducharme et al (22) Cochrane review of ICS/LABA free combinations | |||||
| Aubier, 1999 (39) Single inhaler | 46 | 57:43 | NR | 73 | 16 |
| Separate inhalers | 48 | 50:50 | NR | 73 | 18 |
| Fitzgerald, 1999 (40) | 36 | 53:47 | NR | 79 | NR |
| OPTIMA (18) Low dose ICS | 37 | 45:55 | NR | 86 | NR |
| (O'Byrne, 2001) High dose ICS | 37 | 41:59 | NR | 87 | NR |
| FACET (16) Low dose ICS | 41 | 50:50 | NR | 76 | NR |
| (Pauwels, 1997) High dose ICS | 42 | 47:53 | NR | 76 | NR |
| van der Molen, 1997 (41) | 41 | 49:51 | NR | 68 | 25 |
| Chauhan, Ducharme (33) Cochrane review of addition to ICS of LABAs versus anti-leukotrienes | |||||
| Bjermer, 2003 (42) | 41 | 45:55 | White 77.4% Black 0.5% Asian 7.4% Other 14.7% |
73 | 19 |
| Ilowite, 2004 (43) | 38 | 37:63 | White 85.6% Black 7.7% Hispanic 5.1% |
74 | 19 |
| Price, 2011 (44) | 50 | 39:61 | White 98% Other 2% |
NR | NR |
BUD, budesonide; FORM, formoterol; FP, fluticasone propionate; ICS, inhaled corticosteroid; NR, not reported; SAL, salmeterol.